Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Legal Other
confidence 85%
filed 2026-07-22
EX-99.1
Sigma Lithium discloses a regulatory enforcement action by SUPRAM (Minas Gerais environmental authority) involving fines of approximately US$540,000 for environmental violations from 2013–2022, and the company's initiation of settlement negotiations (a "TAC Agreement") with the State Government. The company also discloses estimated capex of US$1,000,000 to comply with required environmental procedure adjustments. This is a material legal/regulatory matter involving significant financial exposure and operational impact (partial suspension of activities), though the company denies wrongdoing and is actively negotiating a settlement.
View raw filing on EDGAR →
6-K
Legal Other
confidence 85%
filed 2026-07-20
Cemex disclosed receipt of a Statement of Objections from the European Commission regarding antitrust investigations initiated in 2023 concerning the company's admixtures activity in France and Germany. While the company states it cannot yet assess the likely outcome or material adverse impact, the initiation of formal EC enforcement proceedings (evidenced by the SO) is a material regulatory event that would affect a reasonable investor's assessment of legal and financial risk. This is a legal/regulatory matter that does not fit the specific `material_litigation` category (which typically covers lawsuits and settlements) but clearly qualifies as a material legal event.
View raw filing on EDGAR →
6-K
Legal Other
confidence 75%
filed 2026-07-16
EX-99.1
This exhibit is a formal response by Cementos Pacasmayo to an official letter (No. 3113-2026-SMV/11.1) from Peru's Superintendency of the Securities Market (SMV) regarding disclosure obligations related to Holcim's acquisition of controlling interest and the mandatory tender offer. The company's response addresses regulatory compliance questions about what material events were required to be disclosed under Peruvian securities law, including arguments about the scope of disclosure obligations for share purchase agreements, due diligence reports, and valuation documents. This is a regulatory/legal matter involving securities law compliance and disclosure obligations, not a discrete operational or financial event, making it a legal_other classification.
View raw filing on EDGAR →
6-K
Legal Other
confidence 85%
filed 2026-07-14
The 6-K discloses a court order by the Court of Milan (July 9, 2026) revoking a preliminary suspension order and restoring the effectiveness of a corporate purpose amendment to the Company's bylaws. This is a material legal/regulatory event affecting the Company's strategic initiatives and governance. The underlying civil action challenging the validity of shareholder resolutions remains pending, but the immediate disclosure concerns the successful outcome of the precautionary appeal, which the Court determined favored the Company's interest in maintaining the amendment's effectiveness given significant investments already made.
View raw filing on EDGAR →
6-K
Legal Other
confidence 85%
filed 2026-07-13
Moolec received a winding-up petition filed by Linklaters LLP on July 8, 2026, seeking liquidation of the company based on an alleged USD 2.3 million debt for legal fees from former management. The company disputes the claim entirely and intends to contest the petition vigorously. While this is a legal/regulatory matter rather than a bankruptcy filing (the petition has not yet resulted in a winding-up order), it represents a material legal threat to the company's continued existence and operations, including blocking the return of holdback shares to shareholders. The event does not fit the specific `bankruptcy_filing` category because no winding-up order has been granted—only a petition filed with a hearing scheduled for November 2026—but it is clearly a material legal event that threatens the registrant's viability.
View raw filing on EDGAR →
8-K
Legal Other
confidence 75%
filed 2026-07-13
The filing discloses a material legal development: a U.S. District Court temporary restraining order (TRO) issued on June 25, 2026, followed by a Magistrate Judge's Memorandum on July 10, 2026 stating that "at this time there is no TRO in place." This represents a significant change in the company's legal status regarding court-ordered restrictions, which would materially affect investor assessment of litigation risk and operational constraints. While the specific underlying dispute is not detailed, the reversal or lifting of a TRO is a material legal event that does not fit a more specific category.
View raw filing on EDGAR →
8-K
Legal Other
confidence 75%
filed 2026-07-10
Item 1.01
Solésence entered into a Settlement Agreement with Refy Beauty Ltd on July 6, 2026, to settle disputes over consumer care products. The settlement requires payment of $938,000 over twelve months and includes a six-month exclusivity period for SPF product development. While this is a material definitive agreement involving a significant financial obligation ($938,000), it is fundamentally a legal settlement of a dispute rather than a financial obligation creation (debt_issuance), operational partnership, or other specific event type. The settlement is material to investors as it resolves a dispute and commits the company to substantial payments, but the core nature is legal/regulatory dispute resolution.
View raw filing on EDGAR →
8-K
Legal Other
confidence 72%
filed 2026-07-10
Item 8.01
The disclosure centers on management's investigation and allegations of market manipulation and improper trading in Cycurion's stock, including evidence of spoofing, short-sale circuit breaker violations, and abnormal trading volumes (89.9M shares traded against 86.5M float in October 2025; 45% intraday collapse in March 2026). Management states it is "in contact with NASDAQ" and intends to "pursue those parties responsible for improper trading and market manipulation." While the letter also discusses business performance and the decision to decline a reverse split, the substantive disclosure focuses on the company's forensic review findings and stated intention to pursue legal/regulatory remedies for suspected market abuse—a legal/regulatory matter material to investors assessing trading integrity and potential enforcement outcomes.
View raw filing on EDGAR →
8-K
Legal Other
confidence 75%
filed 2026-07-10
Item 1.01
The filing discloses entry into a Release Agreement settling a dispute with the former president of a wholly-owned subsidiary, with the Company agreeing to pay CAD$1,500,000 (approximately US$1.06 million). While Item 1.01 typically covers M&A activity, this is a settlement agreement resolving a dispute rather than an acquisition, merger, or change of control. The event is material due to the significant cash outlay and resolution of a dispute with a former executive, but it is fundamentally a legal settlement rather than a transaction in the M&A sense, making legal_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Legal Other
confidence 85%
filed 2026-07-07
Item 8.01
The disclosure centers on an FDA Warning Letter issued to IMS (a subsidiary) on July 2, 2026, citing CGMP violations at its South El Monte manufacturing facility. This is a regulatory enforcement action that could materially impact the company's ability to manufacture and distribute products. While the Warning Letter does not currently direct cessation of production, the company acknowledges uncertainty about FDA satisfaction with remediation efforts and the possibility of "additional regulatory or legal action" without further notice, creating material regulatory and operational risk.
View raw filing on EDGAR →
8-K
Legal Other
confidence 85%
filed 2026-07-06
Item 8.01
Invivyd received a Notice of Termination of the Emergency Use Authorization (EUA) for PEMGARDA from the FDA, effective June 29, 2027, following HHS's announcement of termination of the COVID-19 EUA declaration. This is a material regulatory event that eliminates the company's primary authorized product and revenue source, but it is fundamentally a regulatory/legal matter rather than a financial restatement, going-concern issue, or other specific category. The company is in dialogue with the FDA regarding next steps, including potential Biologics License Application (BLA) submission, but the immediate event is the loss of regulatory authorization.
View raw filing on EDGAR →
6-K
Legal Other
confidence 85%
filed 2026-07-06
EX-99.1
This press release discloses a law enforcement action by the FBI involving seizure of domains associated with NetNut (Alarum's subsidiary), resulting in service disruptions that the Company acknowledges are "likely to have a material adverse effect on the Company's operations, financial results and its ability to provide certain services to customers." While the disclosure involves potential regulatory/law enforcement investigation rather than a formal litigation filing or settlement, it is a material legal/regulatory event that does not fit the specific categories of material_litigation (no lawsuit filed), cybersecurity_incident (no breach disclosed), or covenant_breach (no debt default). The domain seizures and ongoing investigation constitute a significant legal/regulatory matter warranting disclosure.
View raw filing on EDGAR →
6-K
Legal Other
confidence 85%
filed 2026-07-02
EX-99.1
Alarum Technologies discloses that the FBI has seized domains associated with its subsidiary NetNut Ltd. in connection with residential proxy network operations. This is a material legal/regulatory event involving law enforcement action against the company's infrastructure. While the company states it will cooperate, the seizure itself represents a significant regulatory development that would affect a reasonable investor's assessment of legal and operational risk.
View raw filing on EDGAR →
8-K
Legal Other
confidence 75%
filed 2026-06-30
Item 8.01
The Company received an SEC inquiry on March 24, 2026 regarding non-compliance and failure to file mandatory periodic reports, with the Company requesting the SEC refrain from revoking its registration under Section 12(j) or suspending trading under Section 12(k), materially threatening the Company's continued listing and public status.
View raw filing on EDGAR →
6-K
Legal Other
confidence 75%
filed 2026-06-29
CASI Pharmaceuticals announced settlement of an arbitration proceeding with Acrotech Biopharma regarding termination of a license agreement for exclusive commercialization rights to Evomela® in China. The settlement rescinded the purported termination and restored the License Agreement to full force and effect, subject to revised terms including minimum purchase obligations. This is a material legal resolution affecting the Company's rights to a key commercial asset, but does not fit the specific categories of material_litigation (which typically involves lawsuits filed against the registrant or government investigations) or other defined event types; it is a settlement of a contractual dispute that materially affects the Company's business operations and rights.
View raw filing on EDGAR →
6-K
Legal Other
confidence 85%
filed 2026-06-26
The 6-K discloses a court order in a precautionary proceeding initiated by minority shareholders challenging two shareholder resolutions. The Court denied suspension of the May 2024 multiple voting rights resolution but granted suspension of the October 29, 2025 corporate purpose amendment pending further proceedings, citing concerns about overly broad language referencing the Italian "Golden Power" regime. The Company has filed an appeal scheduled for July 9, 2026. This is a material legal/regulatory event affecting corporate governance and the Company's operational scope, but does not fit the specific categories of material_litigation (no lawsuit against the Company), governance_other (the event is clearly legal/regulatory in nature), or other named types.
View raw filing on EDGAR →
6-K
Legal Other
confidence 85%
filed 2026-06-26
EX-99.1
Northern Dynasty announces that oral arguments were held on June 25, 2026 in Alaska Federal District Court regarding its case seeking withdrawal of the EPA's veto of the Pebble Project. This is a material legal/regulatory event—the outcome of this litigation directly affects the company's ability to develop its principal asset. The forward-looking statements emphasize the company's dependence on "success in its legal action against the EPA and the USACE" and the risk that "any action taken by the EPA...will ultimately not be successful in restricting or prohibiting development of the Pebble Project," underscoring the materiality of this court proceeding to investors.
View raw filing on EDGAR →
6-K
Legal Other
confidence 75%
filed 2026-06-22
EX-99.1
PicPay discloses an investigation by Brazil's Federal District into alleged improper payroll deductions affecting public servants involving a wage-advance product. While the company characterizes the product as enabling early access to earned wages (not a loan) and notes it represented only ~BRL 9 million in accumulated revenues, the disclosure of a government investigation into the company's operations is a material legal/regulatory event that would affect investor assessment of regulatory risk and compliance exposure.
View raw filing on EDGAR →
8-K
Legal Other
confidence 85%
filed 2026-06-22
Item 7.01
The disclosure reports closure of a DOJ Antitrust Division grand jury investigation into health insurance practices, with the Company cleared of criminal investigation, but simultaneously reveals an ongoing civil investigative demand from the same division. This is a material legal/regulatory event involving government investigation that does not fit a specific named category (not litigation, not a settlement, not a covenant breach). The dual nature—closure of criminal inquiry but continuation of civil investigation—represents a significant regulatory development affecting the Company's legal exposure and business operations in healthcare.
View raw filing on EDGAR →
6-K
Legal Other
confidence 75%
filed 2026-06-15
Moody's downgraded Televisa's senior unsecured ratings from 'Ba1' to 'Ba2' and assigned a 'Ba2' corporate family rating with a Stable outlook. While this is a credit-rating action rather than a discrete legal or regulatory event, it is a material disclosure affecting the registrant's cost of capital and financial standing. The downgrade signals increased credit risk and would affect a reasonable investor's assessment of the company's financial condition and debt obligations.
View raw filing on EDGAR →